(NASDAQ: MRNA) Moderna's forecast annual revenue growth rate of 9.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.6%.
Moderna's revenue in 2026 is $2,225,000,000.On average, 27 Wall Street analysts forecast MRNA's revenue for 2026 to be $843,567,586,634, with the lowest MRNA revenue forecast at $701,121,319,653, and the highest MRNA revenue forecast at $933,638,067,427. On average, 26 Wall Street analysts forecast MRNA's revenue for 2027 to be $973,713,479,586, with the lowest MRNA revenue forecast at $705,089,182,243, and the highest MRNA revenue forecast at $1,424,462,669,810.
In 2028, MRNA is forecast to generate $1,170,916,250,309 in revenue, with the lowest revenue forecast at $854,280,815,627 and the highest revenue forecast at $1,453,428,066,717.